Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey G. Supko, Ph.D.

Co-Author

This page shows the publications co-authored by Jeffrey Supko and Richard Penson.
Connection Strength

0.140
  1. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
    View in: PubMed
    Score: 0.060
  2. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229.
    View in: PubMed
    Score: 0.050
  3. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8.
    View in: PubMed
    Score: 0.017
  4. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clin Cancer Res. 1999 Jun; 5(6):1299-305.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.